Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 most shorted penny stocks to buy.
More than 500% upside potential as of the April 23 close supports a highly bullish stance on the stock. Recent developments on the ongoing clinical trials also back the argument. On March 23, Anavex Life Sciences Corp. (NASDAQ:AVXL) released new data on blarcamesine at the AD/PD 2026 conference that was obtained during the ANAVEX2-73-AD-004 phase IIb/III clinical trial, which includes the extended access program, ANAVEX2-73-AD-EP-004.
Billion Photos/Shutterstock.com
It has been found through clinical data that patients possessing the SIGMAR1 and COL24A1 wild-type gene, belonging to the category of ABCLEAR32, derive greater benefit from blarcamesine treatment.
Analysis of the MRI biomarkers showed an extremely strong correlation between decreased atrophy and benefits in both primary and secondary endpoints, such as cognitive performance, daily activities, and overall cognitive and functional improvements. When analyzing the genetic cohort ABCLEAR32 group of participants for precision medicine, the correlation was even stronger, with the R value increased by 78% for the ADAS-Cog13 test, thus showing results that fall into a very suggestive category for clinical relevance.
These findings strongly support the precision medicine strategy applied by Anavex, which involves using both genetic and biomarker markers to find patients who could be responsive to the treatment.
Anavex Life Sciences Corp. (NASDAQ:AVXL) is involved in the development of novel therapeutics for various diseases like Alzheimer’s disease, several types of cancer, schizophrenia, neurodevelopmental disorders, CNS disorders, and more. Its primary drug ANAVEX 2-73 (blarcamesine) has completed different phases of clinical trail for different diseases like phase 2a and a phase 2b/3 clinical trial for Alzheimer’s and phase 2/3 study in paediatric patients with Rett syndrome.
While we acknowledge the risk and potential of AVXL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AVXL and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center